A Path to Reverse Enzalutamide Resistance in Advanced Prostate Cancer

Researchers identify complex cascade of events, a “metabolic switch”

A Cleveland Clinic research team has discovered a biological pathway that could ultimately help men overcome resistance to androgen receptor antagonist therapy in advanced prostate cancer.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

Results from their study of animal models of prostate cancer and patient tissue were published online in the medical journal, eLife.

Resistance inevitably develops

While metastatic prostate cancer responds initially to medical or surgical castration in virtually all men, the disease eventually progresses to castration-resistant prostate cancer (CRPC). Enzalutamide, a potent next-generation AR antagonist, is a next line of defense and prolongs survival for metastatic CRPC patients. However, most men eventually develop resistance to the drug, leading to disease lethality.

“In prostate cancer, we know that a hormone-receptor complex instructs cells to proliferate,” says lead author Nima Sharifi, MD, who holds appointments in Cleveland Clinic’s Lerner Research Institute Department of Cancer Biology, Glickman Urological & Kidney Institute and Taussig Cancer Institute. “Enzalutamide blocks this interaction, rendering androgens inactive.”

Advertising Policy

Metabolic switch

Dr. Sharifi’s research team discovered a complex cascade of events—a “metabolic switch”—that occurs when androgen receptors are blocked with enzalutamide. Results show that enzalutamide treatment causes levels of the enzyme 11β-HSD2 to plummet, which in turn creates a surplus of cortisol in tumor cells. This excess cortisol activates its own receptor-protein complex, which then assumes the role of the disabled androgen receptor, prompting the tumor to increase production of androgens.

Since simply blocking cortisol from its receptor is not compatible with life, Dr. Sharifi’s team searched for an alternative means of turning off this metabolic switch. In their prostate cancer models, they found that restoring levels of 11β-HSD2 reversed enzalutamide resistance.


GR stimulation with enzalutamide resistance in prostate cancer is tightly regulated by glucocorticoid metabolism in target tissues. (Reprinted with permission from Sharifi et al, eLife, 2017)

Advertising Policy

A step closer, but further study needed

“This is a major discovery that demonstrates how tweaking changes in metabolism induced by hormonal therapy can offer major benefits to patients in prostate and possibly other cancers,” Dr. Sharifi explains. “We need additional studies to determine how to safely increase 11β-HSD2 in patients, but we are a step closer to finding answers and hopefully prolonging the lives of men who are in the unfortunate situation of being resistant to all current therapies.”